Kinetic evaluation of an IV bolus of MR contrast media

Citation
Jt. Heverhagen et al., Kinetic evaluation of an IV bolus of MR contrast media, MAGN RES IM, 19(7), 2001, pp. 1025-1030
Citations number
25
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging
Journal title
MAGNETIC RESONANCE IMAGING
ISSN journal
0730725X → ACNP
Volume
19
Issue
7
Year of publication
2001
Pages
1025 - 1030
Database
ISI
SICI code
0730-725X(200109)19:7<1025:KEOAIB>2.0.ZU;2-H
Abstract
Currently, it is assumed that the pharmacokinetic properties of the first m inutes of an I.V. MR contrast media bolus are similar to those of an I.V. i odinated contrast media bolus used in CT. Correct timing of an MRA examinat ion is crucial for obtaining sufficient arterial contrast. This study sough t to evaluate the temporal change of arterial signal intensity within 150 s after I.V. bolus injection of Gd-DTPA. Thirty consecutive patients (14 wom en/16 men; mean age: 51 +/- 11 years) were prospectively examined with a 1. 0 Tesla clinical scanner. A single axial slice was acquired in 1.25 sec wit h manufacturer provided gradient echo sequence through the aorta at the lev el of the renal arteries. Investigation was started simultaneously to the a pplication of contrast media (0.1 mmol/kg bodyweight Gd-DTPA at three diffe rent rates 2 mL/sec, 3 mL/sec and 4 mL/sec) and repeated for 2.5 min. An ad ditional echo Doppler examination excluded patients with any cardiac disord ers. Maximum signal (1300% increase compared to the basic value) in the aor ta was achieved 20 +/- 6 sec after start of bolus injection. Then a plateau phase was maintained for the remaining investigation time (2.5 min). No si gnificant difference was shown for different injection rates. After a bolus injection of Gd-DTPA the arterial contrast remains on a high level for at least 2 min. However, correct timing of the bolus arrival is still crucial to discriminate arteries and veins. An injection rate between 2 mL/sec and 4 mL/sec has no influence on early contrast media dynamics. (C) 2001 Elsevi er Science Inc. All rights reserved.